| Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients A Curti, L Ruggeri, A D'Addio, A Bontadini, E Dan, MR Motta, S Trabanelli, ... Blood, The Journal of the American Society of Hematology 118 (12), 3273-3279, 2011 | 494 | 2011 |
| Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25− into CD25+ T regulatory cells A Curti, S Pandolfi, B Valzasina, M Aluigi, A Isidori, E Ferri, V Salvestrini, ... Blood 109 (7), 2871-2877, 2007 | 465 | 2007 |
| Nucleofection is an efficient nonviral transfection technique for human bone marrow–derived mesenchymal stem cells M Aluigi, M Fogli, A Curti, A Isidori, E Gruppioni, C Chiodoni, MP Colombo, ... Stem cells 24 (2), 454-461, 2006 | 214 | 2006 |
| Real-time quantitation of minimal residual disease in inv (16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state S Buonamici, E Ottaviani, N Testoni, V Montefusco, G Visani, F Bonifazi, ... Blood, The Journal of the American Society of Hematology 99 (2), 443-449, 2002 | 178 | 2002 |
| BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients G Visani, L Malerba, PM Stefani, S Capria, P Galieni, F Gaudio, ... Blood, The Journal of the American Society of Hematology 118 (12), 3419-3425, 2011 | 170 | 2011 |
| Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2, 3-dioxygenase A Curti, M Aluigi, S Pandolfi, E Ferri, A Isidori, V Salvestrini, I Durelli, ... Leukemia 21 (2), 353-355, 2007 | 133 | 2007 |
| Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis F Palandri, M Breccia, M Bonifacio, N Polverelli, EM Elli, G Benevolo, ... Cancer 126 (6), 1243-1252, 2020 | 129 | 2020 |
| The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia–analysis of 848 patients G Visani, P Bernasconi, M Boni, GL Castoldi, S Ciolli, M Clavio, MC Cox, ... Leukemia 15 (6), 903-909, 2001 | 113 | 2001 |
| BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia F Loscocco, G Visani, S Galimberti, A Curti, A Isidori Frontiers in oncology 9, 939, 2019 | 105 | 2019 |
| Differences among young adults, adults and elderly chronic myeloid leukemia patients F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ... Annals of Oncology 26 (1), 185-192, 2015 | 104 | 2015 |
| Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission M Bocchia, A Sicuranza, E Abruzzese, A Iurlo, S Sirianni, A Gozzini, ... Frontiers in Oncology 8, 194, 2018 | 100 | 2018 |
| Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ... The Lancet 401 (10373), 269-280, 2023 | 99 | 2023 |
| Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients A Isidori, M Tani, F Bonifazi, P Zinzani, A Curti, MR Motta, S Rizzi, ... Haematologica 90 (2), 225-231, 2005 | 93 | 2005 |
| Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study PP Piccaluga, G Visani, SA Pileri, S Ascani, T Grafone, A Isidori, ... Leukemia 16 (9), 1609-1614, 2002 | 91 | 2002 |
| Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas PP Piccaluga, G Martinelli, M Rondoni, M Malagola, S Gaitani, A Isidori, ... Leukemia & lymphoma 45 (9), 1791-1795, 2004 | 85 | 2004 |
| The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment A Isidori, V Salvestrini, M Ciciarello, F Loscocco, G Visani, S Parisi, ... Expert review of hematology 7 (6), 807-818, 2014 | 83 | 2014 |
| Immunotherapy in acute myeloid leukemia: where we stand A Isidori, C Cerchione, N Daver, C DiNardo, G Garcia-Manero, ... Frontiers in oncology 11, 656218, 2021 | 82 | 2021 |
| Stem cell mobilization and collection in patients with liver cirrhosis S Lorenzini, A Isidori, L Catani, A Gramenzi, S Talarico, F Bonifazi, ... Alimentary pharmacology & therapeutics 27 (10), 932-939, 2008 | 77 | 2008 |
| Iron toxicity–Its effect on the bone marrow A Isidori, L Borin, E Elli, R Latagliata, B Martino, G Palumbo, F Pilo, ... Blood Reviews 32 (6), 473-479, 2018 | 70 | 2018 |
| Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA A Olivieri, G Gini, C Bocci, M Montanari, S Trappolini, J Olivieri, M Brunori, ... The Oncologist 17 (5), 663-672, 2012 | 63 | 2012 |
pier paolo piccalugaProfessore Associato, Università degli Studi di Bologna在 unibo.it 的电子邮件经过验证
